Dawn Matthews gave an invited presentation at the Society for Nuclear Medicine and Molecular Imaging (SNMMI), describing the Amyloid PET Profile developed by the Quantitative Imaging Biomarkers Alliance Amyloid PET working group. This Profile identifies sources of technical variability that can reduce the statistical power of measuring changes in amyloid in the brain. It provides practical guidelines that can be followed by imaging sites, imaging CROs, and pharmaceutical clinical trial sponsors to optimize amyloid PET measurement. This work represents the collaborative effort of numerous members from industry and academia, co-chaired by Dawn Matthews of ADMdx, Anne Smith of Siemens Healthineers, and Satoshi Minoshima of the University of Utah.